<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Influenza virus vaccines (inactivated) (IIV4): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Influenza virus vaccines (inactivated) (IIV4): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Influenza virus vaccines (inactivated) (IIV4): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9055" href="/d/html/9055.html" rel="external">see "Influenza virus vaccines (inactivated) (IIV4): Drug information"</a> and <a class="drug drug_patient" data-topicid="11948" href="/d/html/11948.html" rel="external">see "Influenza virus vaccines (inactivated) (IIV4): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F9560252"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Afluria Quadrivalent;</li>
<li>Fluad Quadrivalent;</li>
<li>Fluarix Quadrivalent;</li>
<li>Flucelvax Quadrivalent;</li>
<li>Flulaval Quadrivalent;</li>
<li>Fluzone Quadrivalent</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52912096"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Afluria Tetra;</li>
<li>Fluad;</li>
<li>Fluad Pediatric;</li>
<li>Flucelvax Quad;</li>
<li>Flulaval Tetra;</li>
<li>Fluzone High-Dose Quadrivalent;</li>
<li>Fluzone Quadrivalent;</li>
<li>Influvac Tetra</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1047915"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Vaccine</span>;</li>
<li>
<span class="list-set-name">Vaccine, Inactivated Virus</span></li></ul></div>
<div class="block dop drugH1Div" id="F9560266"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form:</b> Products with similar names but containing different strains may be circulating globally due to differences in recommendations between northern and southern hemisphere countries. In addition, recommendations related to use of influenza vaccines and approved ages may vary per country.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="debf7e1f-541b-494a-93f4-4e2ebea00676">Immunization, annual</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Immunization, annual:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Influenza seasons vary in the timing and duration from year to year. In general, vaccination should preferably occur by the end of October (in the United States) to ensure optimal immunity prior to onset and for the full duration of influenza activity in the community; patients who should receive 2 doses should begin vaccination as soon as vaccine is available so that the second dose can be given by the end of October. Vaccination should continue throughout the influenza season as long as vaccine is available. According to ACIP, doses administered ≤4 days before minimum interval or age are considered valid; however, local or state mandates may supersede this timeframe (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kroger.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kroger.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Product-specific dosing: Note:</b> In infants and young children, the dose volume may be different for some formulations (eg, 0.25 mL vs 0.5 mL per dose); use caution when verifying product selection and dose volume.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Afluria Quadrivalent</i>
<i>:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Infants ≥6 months and Children ≤35 months: IM: 0.25 mL per dose for a total of 1 or 2 doses per season, dependent upon vaccination history (see table regarding dose number).</p>
<p style="text-indent:-2em;margin-left:8em;">Children 3 to 8 years: IM: 0.5 mL per dose for a total of 1 or 2 doses per season, dependent upon vaccination history (see table regarding dose number).</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥9 years and Adolescents &lt;18 years: IM: 0.5 mL per dose as a single dose per season.</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents ≥18 years: IM or via PharmaJet Stratis Needle-Free Injection System: 0.5 mL per dose as a single dose per season.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Fluarix Quadrivalent, Flucelvax Quadrivalent, FluLaval Quadrivalent:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Infants ≥6 months and Children &lt;9 years: IM: 0.5 mL per dose for a total of 1 or 2 doses per season, dependent upon vaccination history (see table regarding dose number).</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥9 years and Adolescents: IM: 0.5 mL per dose as a single dose per season.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Fluzone Quadrivalent:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Infants ≥6 months and Children ≤35 months: IM: 0.25 mL or 0.5 mL per dose for a total of 1 or 2 doses per season, dependent upon vaccination history. If 2 doses required, the schedule can be completed as any combination of 0.25 mL or 0.5 mL doses administered ≥4 weeks apart (see table regarding dose number).</p>
<p style="text-indent:-2em;margin-left:8em;">Children 3 to 8 years: IM: 0.5 mL per dose for a total of 1 or 2 doses per season, dependent upon vaccination history (see table regarding dose number).</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥9 years and Adolescents: IM: 0.5 mL per dose as a single dose per season.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Number of doses per season: </b></p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<caption style="text-align:left;">
<b>Number of Influenza Vaccine Doses Recommended Per Season<sup>a</sup></b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><tfoot valign="top">
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<sup>a</sup> Dose volume product dependent; see product-specific dosing above.</p>
<p style="text-indent:0em;">
<sup>b</sup> A child turning 9 years of age between the first and second dose should still receive 2 doses if they meet criteria for receipt of 2 doses.</p></td></tr></tfoot>
<tbody valign="top">
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<b>Note:</b> The number of doses recommended per flu season is dependent upon age and vaccination history (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37641884','lexi-content-ref-Grohskopf.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37641884','lexi-content-ref-Grohskopf.1'])">Ref</a></span>).</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;">Infants ≥6 months and Children &lt;9 years at time of first dose<sup>b</sup></p></td>
<td align="left">
<p style="text-indent:0em;">• If it is the patient's first season of vaccination <b>or</b></p>
<p style="text-indent:0em;margin-top:2em;">• If patient received ≤1 dose of trivalent or quadrivalent influenza vaccine prior to July 1 preceding the current flu season start <b>or</b></p>
<p style="text-indent:0em;margin-top:2em;">• If the vaccination history cannot be determined</p></td>
<td align="left">
<p style="text-indent:0em;">Two doses (separated by ≥4 weeks)<sup>b</sup></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">If the patient received ≥2 doses of trivalent or quadrivalent influenza vaccine prior to July 1 preceding the current flu season start. The 2 doses need not have been received during the same season or consecutive seasons.</p></td>
<td align="left">
<p style="text-indent:0em;">One dose</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Children ≥9 years and Adolescents</p></td>
<td align="left">
<p style="text-indent:0em;">Any history</p></td>
<td align="left">
<p style="text-indent:0em;">One dose</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">
<b>Canadian labeling:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Afluria Tetra:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Children 5 to &lt;9 years: IM: 0.5 mL per dose (1 dose per season); a second dose should be administered 4 weeks after the first in previously unvaccinated patients.</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥9 years and Adolescents: IM: 0.5 mL per dose (1 dose per season).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Fluzone Quadrivalent:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Infants and Children 6 to 35 months: IM: 0.25 mL or 0.5 mL per dose; NACI recommendation: 0.5 mL per dose (1 dose per season); a second dose should be administered 4 weeks after the first in previously unvaccinated patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NACI.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NACI.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Children 3 to &lt;9 years: IM: 0.5 mL per dose (1 dose per season); a second dose should be administered 4 weeks after the first in previously unvaccinated patients.</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥9 years and Adolescents: IM: 0.5 mL per dose (1 dose per season).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Fluad Pediatric:</i> Infants and Children 6 months to &lt;2 years: IM: 0.25 mL per dose (1 dose per season); a second dose should be administered 4 weeks after the first in previously unvaccinated patients and in patients who were vaccinated for the first time last season and only 1 dose was received.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Flucelvax Quad:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Infants ≥6 months and Children &lt;9 years: 0.5 mL per dose (1 dose per season); a second dose should be administered 4 weeks after the first in previously unvaccinated patients.</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥9 years and Adolescents: IM: 0.5 mL per dose (1 dose per season).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>FluLaval Tetra:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Infants ≥6 months and Children &lt;9 years: IM: 0.5 mL per dose (1 dose per season); a second dose should be administered 4 weeks after the first in previously unvaccinated patients.</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥9 years and Adolescents: IM: 0.5 mL per dose (1 dose per season).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Influvac Tetra:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Infants ≥6 months and Children &lt;9 years: IM, Deep SUBQ: 0.5 mL per dose (1 dose per season); a second dose should be administered 4 weeks after the first in previously unvaccinated patients.</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥9 years and Adolescents: IM, Deep SUBQ: 0.5 mL per dose (1 dose per season).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51113961"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51113962"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F9600936"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9055" href="/d/html/9055.html" rel="external">see "Influenza virus vaccines (inactivated) (IIV4): Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Influenza seasons vary in the timing and duration from year to year. In general, vaccination should preferably occur during September or October (in the United States) to ensure optimal immunity prior to onset and for the full duration of influenza activity in the community. Early vaccination (in July or August) for an upcoming influenza season has been associated with suboptimal immunity before the end of an influenza season, particularly in older adults. Vaccination should continue throughout the influenza season as long as vaccine is available. The CDC does not recommend revaccination later in the season for those persons who have already been fully vaccinated. <b>International considerations:</b> Products with similar names but containing different strains may be circulating globally due to differences in recommendations between northern and southern hemisphere countries. In addition, recommendations related to use of influenza vaccines and approved ages may vary per country.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dedd7ff3-b860-4044-a1c5-28d0290fe43d">Immunization</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Immunization:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Afluria Quadrivalent:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Adults ≤64 years of age: <b>IM</b> or via PharmaJet Stratis Needle-Free Injection System: 0.5 mL per dose as a single dose (1 dose per season).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults &gt;64 years of age: <b>IM:</b> 0.5 mL per dose as a single dose (1 dose per season).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Fluarix Quadrivalent, Flucelvax Quadrivalent, FluLaval Quadrivalent, Fluzone Quadrivalent:</i>
<b>IM:</b> 0.5 mL/dose (1 dose per season).</p>
<p style="text-indent:0em;margin-left:2em;margin-top:2em;">Canadian labeling:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Afluria Tetra, FluLaval Tetra, Fluviral, Fluzone Quadrivalent:</i>
<b>IM:</b> 0.5 mL/dose (1 dose per season).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Influvac Tetra:</i>
<b>IM, SubQ:</b> 0.5 mL/dose (1 per season).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991334"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50988702"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F9560258"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adult and pediatric patients unless otherwise specified. Incidence of adverse events for the second dose of vaccine (when warranted) was typically milder than first dose.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia (infants, children, and adolescents: 9% to 32%; adults and older adults: 4% to 8%), diarrhea (4% to 24%), nausea (≤12%), vomiting (infants, children, and adolescents: ≤15%; adults and older adults: ≤3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Bruising at injection site (≤11%), erythema at injection site (1% to 37%), induration at injection site (≤18%), pain at injection site (17% to 67%), swelling at injection site (≤25%), tenderness at injection site (21% to 69%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Drowsiness (infants and children: 8% to 38%), fatigue (≤22%), headache (1% to 27%), irritability (infants and children: 2% to 54%), malaise (≤38%), uncontrolled crying (infants and children: 33% to 41%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (4% to 15%), myalgia (3% to 40%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (infants, children, and adolescents: 1% to 15%), rhinorrhea (infants and children: 1% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (infants, children, and adolescents: 1% to 16%; adults and older adults: ≤4%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (infants and children: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Change in appetite (children: 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills (≤8%), shivering (≤9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Flu-like symptoms (infants and children: 1%), nasal congestion (infants, children, and adolescents: 2% to 6%), nasopharyngitis (infants and children: 2%), oropharyngeal pain (1% to 7%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Local: Hematoma at injection site, injection-site pruritus</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain, flushing, presyncope, syncope (shortly after vaccination), tachycardia, vasculitis (including transient renal involvement), vasodilation</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis, ecchymoses, erythema multiforme, erythema of skin, pallor, pruritus, Stevens-Johnson syndrome, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hot flash</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distress, abdominal pain, dysphagia, gastroenteritis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Henoch-Schönlein purpura, lymphadenopathy, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock, anaphylaxis, angioedema, facial edema, hypersensitivity reaction (including oculorespiratory syndrome, an acute, self-limited reaction with ocular and respiratory symptoms) (NACI 2022), nonimmune anaphylaxis, serum sickness, swollen tongue, type 1 hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Abscess at injection site, cellulitis at injection site, inflammation at injection site, rash at injection site, swelling of injected limb (lasting &gt;1 week), warm sensation at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia, Bell palsy, body pain, cranial nerve palsy, dizziness, encephalopathy, facial nerve paralysis, febrile seizure, feeling hot, Guillain-Barre syndrome, hypoesthesia, impaired mobility (of injected limb), insomnia, myasthenia, neuralgia, neuritis, neuropathy (including brachial plexopathy), paralysis (including limb), paresthesia, seizure, transverse myelitis, tremor, vertigo, voice disorder</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Hypokinesia, limb pain, musculoskeletal pain, myelitis (including encephalomyelitis)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Eye pain, eyelid edema, ocular hyperemia, optic neuritis, optic neuropathy, photophobia, swelling of eye</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm, dyspnea, pharyngeal edema, pharyngitis, rhinitis, tonsillitis, wheezing</p></div>
<div class="block coi drugH1Div" id="F9560342"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Severe allergic reaction (eg, anaphylaxis) to any component of the formulation; see manufacturer labeling for all components of each formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">Additional manufacturer contraindications for Afluria Quadrivalent, Fluad Quadrivalent, Fluarix Quadrivalent, FluLaval Quadrivalent, Fluzone High-Dose Quadrivalent, Fluzone Quadrivalent: History of severe allergic reaction (eg, anaphylaxis) to egg protein.</p>
<p style="text-indent:-2em;margin-left:2em;">Additional manufacturer contraindications for Canadian products: Fluad, Fluad Pediatric, FluLaval Tetra, Fluzone High-Dose Quadrivalent, Fluzone Quadrivalent, Influvac Tetra: Hypersensitivity to egg protein.</p>
<p style="text-indent:-2em;margin-left:2em;">Additional contraindications from the Advisory Committee on Immunization Practices (ACIP) (CDC/ACIP [Grohskopf 2023)]:</p>
<p style="text-indent:-2em;margin-left:4em;">Egg-based IIV4 vaccines: Severe allergic reaction (eg, anaphylaxis) to a previous dose of any influenza vaccine.</p>
<p style="text-indent:-2em;margin-left:4em;">Cell culture-based IIV4 (Flucelvax Quadrivalent): Severe allergic reaction (eg, anaphylaxis) to a previous dose of any cell culture-based IIV.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Neither the ACIP nor the Canadian National Advisory Committee on Immunization consider egg allergy a contraindication to influenza vaccination (CDC/ACIP [Grohskopf 2023]; NACI 2023).</p></div>
<div class="block war drugH1Div" id="F9600929"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Oculorespiratory syndrome: Oculorespiratory syndrome (ORS) is an acute, self-limiting reaction to inactivated influenza vaccine (IIV) with one or more of the following symptoms appearing within 2 to 24 hours after the dose: chest tightness, cough, difficulty breathing, facial swelling, red eyes, sore throat, or wheezing. Symptoms resolve within 48 hours of onset. The cause of ORS has not been established, but studies have suggested that it is not IgE mediated. However, because ORS symptoms may be similar to those of an IgE-mediated hypersensitivity reaction, health care providers unsure of etiology of symptoms should seek advice from an allergist/immunologist when determining whether a patient may be revaccinated in subsequent seasons (Demicheli 2018; Skowronski 2005).</p>
<p style="text-indent:-2em;margin-left:4em;">• Shoulder injury related to vaccine administration: Vaccine administration that is too high on the upper arm may cause shoulder injury (eg, shoulder bursitis or tendinopathy) resulting in shoulder pain and reduced range of motion following injection. Use proper injection technique for vaccines administered in the deltoid muscle (eg, injecting in the central, thickest part of the muscle) to reduce the risk of shoulder injury related to vaccine administration (Cross 2016; Foster 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">• Syncope: Syncope has been reported with use of injectable vaccines and may result in serious secondary injury (eg, skull fracture, cerebral hemorrhage); typically reported in adolescents and young adults and within 15 minutes after vaccination. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Acute illness: The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Postpone administration in patients with moderate or severe acute illness (with or without fever); vaccination should not be delayed for patients with mild acute illness (with or without fever) (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Bleeding disorders: Use with caution in patients with a history of bleeding disorders (including thrombocytopenia); bleeding/hematoma may occur from IM administration; if the patient receives antihemophilia or other similar therapy, IM injection can be scheduled shortly after such therapy is administered (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Febrile seizures: Antipyretics have not been shown to prevent febrile seizures; antipyretics may be used to treat fever or discomfort following vaccination (ACIP [Kroger 2023]). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula 2009).</p>
<p style="text-indent:-2em;margin-left:4em;">• Guillain-Barré syndrome: Use with caution in patients with history of Guillain-Barré syndrome (GBS); patients with history of GBS have a greater likelihood of developing GBS than those without. As a precaution, the Advisory Committee on Immunization Practices (ACIP) recommends that patients with a history of GBS and who are not at higher risk for severe influenza complications, and patients known to have experienced GBS within 6 weeks following previous influenza vaccination should generally not be vaccinated (consider influenza antiviral chemoprophylaxis in these patients). The benefits of vaccination may outweigh the potential risks in persons with a history of GBS who are also at higher risk for severe complications of influenza (CDC/ACIP [Grohskopf 2023]). Studies of patients who received the trivalent inactivated influenza vaccine or the monovalent H1N1 influenza vaccine have shown the risk of GBS is lower with vaccination than with influenza infection (Baxter 2013; Greene 2013; Kwong 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">• Neurologic disorders: Some Canadian product labeling recommends delaying therapy in patients with active neurologic disorders. Refer to the Canadian National Advisory Committee on Immunization (NACI) for vaccination recommendations for persons with neurologic or neurodevelopment conditions.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anticoagulant therapy: Use with caution in patients receiving anticoagulant therapy; bleeding/hematoma may occur from IM administration (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Vaccines: In order to maximize vaccination rates, the ACIP, as well as the NACI, recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or nonlive) for which a person is eligible at a single visit, unless contraindications exist. The ACIP prefers each dose of a specific vaccine in a series come from the same manufacturer when possible; however, vaccination should not be deferred because a specific brand is unavailable (ACIP [Kroger 2023]; NACI 2023).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Altered immunocompetence: Postpone vaccination during periods of immunosuppression (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy [including high-dose corticosteroid]) if appropriate; may have a reduced response to vaccination. Inactivated vaccine (IIV or recombinant influenza vaccine [RIV]) is preferred over live virus vaccine (LAIV) for immunocompromised persons, household members, health care workers, and others coming in close contact with severely immunosuppressed persons requiring care in a protected environment. Refer to annual immunization schedule for additional information (ACIP [Kroger 2023]; CDC/ACIP [Grohskopf 2023]). Nonlive vaccines should be administered ≥2 weeks prior to planned immunosuppression when feasible; nonlive vaccines administered during chemotherapy should be readministered after immune competence is regained (ACIP [Kroger 2023]; IDSA [Rubin 2014]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Older adults: Antibody responses may be lower and decline faster in older adults ≥65 years of age compared to younger adults; however, deferral to later in the season may result in missed vaccination opportunities or early season infection (CDC/ACIP [Grohskopf 2023]). Fluzone High-Dose contains 4 times the amount of each influenza antigen compared to other inactivated virus vaccines and was shown to elicit a higher antibody response and may provide better protection against influenza illness in older adults compared to standard dose IIV3 formulations (DiazGranados 2014). For persons ≥65 years of age, the ACIP recommends a higher dose or adjuvanted influenza vaccine (ie, HD-IIV4, RIV4, or aIIV4). If one of these vaccines is not available, then any other age-appropriate vaccine may be used (CDC/ACIP [Grohskopf 2023]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Chicken egg protein: Most products are manufactured with chicken egg protein (expressed as ovalbumin content when content is disclosed on product labeling). The ovalbumin content may vary from season to season and lot to lot of vaccine. The ACIP no longer recommends additional safety monitoring for patients with a history of an allergic reaction related to egg (regardless of severity). Current recommendations state that patients may receive vaccination regardless of severity of egg allergy and no special precautions are required (AAP 2023a; CDC/ACIP [Grohskopf 2023]; Greenhawt 2018; NACI 2023).</p>
<p style="text-indent:-2em;margin-left:4em;">• Gentamicin: Some products are manufactured with gentamicin.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hydrocortisone: Some products may contain hydrocortisone.</p>
<p style="text-indent:-2em;margin-left:4em;">• Kanamycin: Some products are manufactured with kanamycin.</p>
<p style="text-indent:-2em;margin-left:4em;">• Latex: Packaging may contain natural latex rubber.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neomycin: Some products are manufactured with neomycin.</p>
<p style="text-indent:-2em;margin-left:4em;">• Polymyxin: Some products are manufactured with polymyxin.</p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thimerosal: Some products contain thimerosal; hypersensitivity reactions may occur.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Use of this vaccine for specific medical and/or other indications (eg, immunocompromising conditions, hepatic or kidney disease, diabetes) is also addressed in the annual ACIP Recommended Immunization Schedules (refer to CDC schedule for detailed information). Specific recommendations for use of this vaccine in immunocompromised patients with asplenia, cancer, HIV infection, cerebrospinal fluid leaks, cochlear implants, hematopoietic stem cell transplant (prior to or after), sickle cell disease, solid organ transplant (prior to or after), or those receiving immunosuppressive therapy for chronic conditions are available from the Infectious Diseases Society of America (Rubin 2014).</p>
<p style="text-indent:-2em;margin-left:4em;">• Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Other influenza vaccines: Influenza vaccines from previous seasons must not be used. Vaccines formulated for the northern hemisphere may differ in composition from the southern hemisphere vaccine; consult CDC Yellow Book for more information regarding travel vaccines (CDC/ACIP [Grohskopf 2023]).</p></div>
<div class="block foc drugH1Div" id="F9600938"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;">Suspension, Intramuscular:</p>
<p style="text-indent:-2em;margin-left:4em;">Afluria Quadrivalent: (5 mL) [contains thimerosal; may contain egg protein, neomycin sulfate]</p>
<p style="text-indent:-2em;margin-left:4em;">Flucelvax Quadrivalent: (5 mL) [contains thimerosal; may contain polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;">Fluzone Quadrivalent: (5 mL) [contains thimerosal; may contain egg protein, formaldehyde]</p>
<p style="text-indent:-2em;margin-left:2em;">Suspension, Intramuscular [preservative free]:</p>
<p style="text-indent:-2em;margin-left:4em;">Fluzone Quadrivalent: (0.5 mL) [may contain egg protein, formaldehyde]</p>
<p style="text-indent:-2em;margin-left:2em;">Suspension Prefilled Syringe, Intramuscular [preservative free]:</p>
<p style="text-indent:-2em;margin-left:4em;">Afluria Quadrivalent: (0.5 mL) [may contain egg protein, neomycin sulfate]</p>
<p style="text-indent:-2em;margin-left:4em;">Fluad: (0.5 mL [DSC]) [contains polysorbate 80; may contain egg protein, formaldehyde, neomycin]</p>
<p style="text-indent:-2em;margin-left:4em;">Fluad Quadrivalent: (0.5 mL) [contains polysorbate 80; may contain egg protein, formaldehyde, neomycin]</p>
<p style="text-indent:-2em;margin-left:4em;">Fluarix Quadrivalent: (0.5 mL) [contains polysorbate 80; may contain egg protein, formaldehyde, gentamicin]</p>
<p style="text-indent:-2em;margin-left:4em;">Flucelvax Quadrivalent: (0.5 mL) [may contain polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;">Flulaval Quadrivalent: (0.5 mL) [may contain egg protein, formaldehyde, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;">Fluzone Quadrivalent: (0.5 mL) [may contain egg protein, formaldehyde]</p></div>
<div class="block geq drugH1Div" id="F9560328"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F16570492"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Prefilled Syringe</b> (Fluad Quadrivalent Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mL (per 0.5 mL): $81.43</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension Prefilled Syringe</b> (Afluria Quadrivalent Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mL (per 0.5 mL): $24.80</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension Prefilled Syringe</b> (Fluarix Quadrivalent Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mL (per 0.5 mL): $23.53</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension Prefilled Syringe</b> (Flucelvax Quadrivalent Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mL (per 0.5 mL): $35.97</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension Prefilled Syringe</b> (Flulaval Quadrivalent Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mL (per 0.5 mL): $23.53</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension Prefilled Syringe</b> (Fluzone High-Dose Quadrivalent Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.7 mL (per 0.7 mL): $77.27</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension Prefilled Syringe</b> (Fluzone Quadrivalent Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mL (per 0.5 mL): $23.56</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52912097"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Injection, suspension:</p>
<p style="text-indent:-2em;margin-left:4em;">Afluria Tetra: Hemagglutinin 60 mcg/0.5 mL (0.5 mL) [contains chicken egg protein, neomycin (may have trace amounts), polymyxin (may contain trace amounts), thimerosal]</p>
<p style="text-indent:-2em;margin-left:4em;">Agriflu: Hemagglutinin 45 mcg/0.5 mL (0.5 mL) [contains chicken egg protein, neomycin (may have trace amounts), kanamycin (may have trace amounts), formaldehyde, polysorbate 80, thimerosal]</p>
<p style="text-indent:-2em;margin-left:4em;">Flucelvax Quad: Haemagglutinin 15 mcg/0.5 mL (5 mL) [contains thimerosal]</p>
<p style="text-indent:-2em;margin-left:4em;">FluLaval Tetra: (5 mL) [contains chicken egg protein, formaldehyde solution, polysorbate 80, thimerosal]</p>
<p style="text-indent:-2em;margin-left:4em;">Fluviral: Hemagglutinin 45 mcg/0.5 mL (5 mL) [contains chicken egg protein, formaldehyde, polysorbate 80, thimerosal]</p>
<p style="text-indent:-2em;margin-left:4em;">Fluzone Quadrivalent: Hemagglutinin 45 mcg/0.5 mL (5 mL) [contains chicken egg protein, formaldehyde, thimerosal]</p>
<p style="text-indent:-2em;margin-left:2em;">Injection, suspension [preservative free]:</p>
<p style="text-indent:-2em;margin-left:4em;">Agriflu: Hemagglutinin 45 mcg/0.5 mL (0.5 mL) [contains chicken egg protein, neomycin (may have trace amounts), kanamycin (may have trace amounts), formaldehyde, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;">Fluad: Hemagglutinin 45 mcg/0.5 mL (0.5 mL) [contains chicken egg protein, formaldehyde, neomycin (may have trace amounts), kanamycin (may have trace amounts), hydrocortisone (may have trace amounts), polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;">Fluad Pediatric: Hemagglutinin 22.5 mcg/0.25 mL (0.25 mL) [contains chicken egg protein, formaldehyde, neomycin (may have trace amounts), kanamycin (may have trace amounts), hydrocortisone (may have trace amounts), polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;">Flucelvax Quad: Haemagglutinin 15 mcg/0.5 mL (0.5 mL)</p>
<p style="text-indent:-2em;margin-left:4em;">Fluzone High-Dose Quadrivalent: Hemagglutinin 60 mcg/0.7 mL (0.7 mL) [contains formaldehyde, ovalbumin]</p>
<p style="text-indent:-2em;margin-left:4em;">Fluzone Quadrivalent: Hemagglutinin 45 mcg/0.5 mL (0.25 ml, 0.5 mL) [contains chicken egg protein, formaldehyde]</p>
<p style="text-indent:-2em;margin-left:4em;">Influvac: Hemagglutinin 45 mcg/0.5 mL (0.5 mL) [contains chicken egg protein, formaldehyde, gentamicin (may have trace amounts), polysorbate 80]</p></div>
<div class="block admp drugH1Div" id="F52614153"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">To prevent syncope-related injuries, adolescents should be vaccinated while seated or lying down. Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kroger.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kroger.1'])">Ref</a></span>). US law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, Vaccine Information Statement (VIS) edition date and date it was provided, and the administering person's name, title, and address be recorded.</p>
<p style="text-indent:-2em;margin-left:2em;">IM: US products: Afluria Quadrivalent, Fluarix Quadrivalent, Flucelvax Quadrivalent, FluLaval Quadrivalent, Fluzone Quadrivalent; Canadian products: Afluria Tetra, Fluad Pediatric, FluLaval Tetra, Fluzone Quadrivalent, Influvac Tetra:</p>
<p style="text-indent:-2em;margin-left:4em;">For IM administration only. Inspect for particulate matter and discoloration prior to administration. Shake well prior to use; for Fluad Pediatric [Canadian product], shake gently. Jet injectors should not be used to administer inactivated influenza vaccines unless otherwise indicated in product labeling. Currently Afluria Quadrivalent is the only influenza vaccine in the United States that can be given IM by a jet-injector device. Prefilled syringes should not be used to deliver smaller dose volumes (eg, do not use a 0.5 mL Fluzone prefilled syringe to deliver a 0.25 mL dose) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Grohskopf.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Grohskopf.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants: IM injection in the anterolateral aspect of the thigh preferred; injection into the gluteal region or areas where there may be a major nerve trunk should generally not be used; however, ACIP indicates that the gluteal muscle can be used in certain circumstances, with care taken to define anatomic landmarks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kroger.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kroger.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children &lt;3 years: IM injection in anterolateral thigh preferred; deltoid muscle can be used if muscle mass is adequate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kroger.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kroger.1'])">Ref</a></span>). If injecting in the deltoid muscle, use proper injection technique (eg, injecting in the central, thickest part of the muscle) to reduce the risk of shoulder injury related to vaccine administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27166466','lexi-content-ref-23636163']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27166466','lexi-content-ref-23636163'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥3 years and Adolescents: IM injection in the deltoid muscle. Use proper injection technique to inject into the deltoid muscle (eg, injecting into the central, thickest part of the muscle) to reduce the risk of shoulder injury related to vaccine administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27166466','lexi-content-ref-23636163']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27166466','lexi-content-ref-23636163'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Afluria Quadrivalent</i> via PharmaJet Stratis Needle-Free Injection System: Adolescents ≥18 years: For IM administration only. For detailed instructions on preparation and administration of a dose, refer to the information available online at www.pharmajet.com.</p>
<p style="text-indent:-2em;margin-left:2em;">SUBQ: <i>Influvac Tetra (Canadian labeling)</i>: Infants ≥6 months, Children, and Adolescents: May administer by deep SUBQ injection. Allow to warm to room temperature prior to use.</p>
<p style="text-indent:-2em;margin-left:2em;">Patients at risk of bleeding (eg, patient receiving antihemophilic factor): For patients at risk of hemorrhage following IM injection, the vaccine should be administered IM if, in the opinion of the physician familiar with the patient's bleeding risk, the vaccine can be administered by this route with reasonable safety. If the patient receives antihemophilia or other similar therapy, IM vaccination can be scheduled shortly after such therapy is administered. A fine needle (23-gauge or smaller) can be used for the vaccination and firm pressure applied to the site (without rubbing) for at least 2 minutes. The patient should be instructed concerning the risk of hematoma from the injection. Patients on anticoagulant therapy should be considered to have the same bleeding risks and treated as those with clotting factor disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kroger.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kroger.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">If a pediatric dose of 0.25 mL is inadvertently administered to a patient ≥36 months of age who should have received a 0.5 mL dose, the remaining volume needed to make the full dose or a full repeat dose should be administered. If the error is discovered after the patient has left the health care setting, a full dose should be given as soon as the patient can return. If a 0.5 mL dose is inadvertently administered to a patient who should have received 0.25 mL, no action needs to be taken; the dose should be counted as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Grohskopf.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Grohskopf.1'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F9560343"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Suspensions should be shaken well prior to use; emulsions <i>(Fluad Quadrivalent)</i> should be gently shaken. Inspect for particulate matter and discoloration prior to administration. Some manufacturers recommend avoiding use if visible particles or discoloration are present in the suspension after shaking. See manufacturer labeling for specific recommendations.</p>
<p style="text-indent:0em;margin-top:2em;">Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection. May administer simultaneously with other vaccines (eg, COVID-19 vaccine). If administering an influenza vaccine that may be more likely to produce an injection site reaction (eg, HD-IIV4 <i>[Fluzone High-Dose]</i> or adjuvanted IIV4 <i>[Fluad Quadrivalent]</i>) simultaneously with a COVID-19 vaccine, administer each vaccine in different limbs if possible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Grohskopf.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Grohskopf.1'])">Ref</a></span>).</p>
<p style="text-indent:0em;margin-top:2em;">To prevent syncope-related injuries, patients should be vaccinated while seated or lying down (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kroger.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kroger.1'])">Ref</a></span>). US law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, Vaccine Information Statement (VIS) edition date and date it was provided, and the administering person's name, title, and address be recorded.</p>
<p style="text-indent:0em;margin-top:2em;">Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kroger.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kroger.1'])">Ref</a></span>). If administering Flucelvax Quadrivalent (ccIIV4) to a person with a history of a severe allergic reaction (eg, anaphylaxis) to any other influenza vaccine, administer in a medical setting with health care supervision able to recognize and manage severe allergic reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Grohskopf.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Grohskopf.1'])">Ref</a></span>).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>IM:</b> For IM administration. Use proper injection technique to inject into the deltoid muscle (eg, injecting into the central, thickest part of the muscle) to reduce the risk of shoulder injury related to vaccine administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27166466','lexi-content-ref-23636163']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27166466','lexi-content-ref-23636163'])">Ref</a></span>). Do not inject into the gluteal region or areas where there may be a major nerve trunk.</p>
<p style="text-indent:0em;margin-top:2em;">
<i>
<i>Afluria Quadrivalent</i></i> via PharmaJet Stratis Needle-free Injection System: For IM administration in adults 18 to 64 years of age only. For detailed instructions on preparation and administration of a dose, refer to the information available online at www.pharmajet.com.</p>
<p style="text-indent:0em;margin-top:2em;">Unless otherwise indicated in product labeling, jet injectors should <b>not</b> be used to administer inactivated influenza vaccines. Currently, <i>Afluria Quadrivalent</i> is the only influenza vaccine licensed in the United States with data about use with a jet-injector device.</p>
<p style="text-indent:0em;margin-top:2em;">
<b>SUBQ: </b>
<i>Influvac Tetra (Canadian product)</i>: May administer by deep SUBQ injection; allow to warm to room temperature prior to use.</p>
<p style="text-indent:0em;margin-top:2em;">If a pediatric dose of 0.25 mL is inadvertently administered to a patient who should have received a 0.5 mL or 0.7 mL dose, the remaining volume needed to make the full dose or a full repeat dose should be administered. If the error is discovered after the patient has left the health care setting, a full dose should be given as soon as the patient can return (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Grohskopf.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Grohskopf.1'])">Ref</a></span>).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> For patients at risk of hemorrhage following IM injection, the vaccine should be administered IM if, in the opinion of the physician familiar with the patient's bleeding risk, the vaccine can be administered by this route with reasonable safety. If the patient receives antihemophilia or other similar therapy, intramuscular vaccination can be scheduled shortly after such therapy is administered. A fine needle (≤23-gauge) can be used for the vaccination and firm pressure applied to the site (without rubbing) for at least 2 minutes. The patient should be instructed concerning the risk of hematoma from the injection. Patients on anticoagulant therapy should be considered to have the same bleeding risks and treated as those with clotting factor disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kroger.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kroger.1'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F9560264"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Store all products between 2°C to 8°C (36°F to 46°F). Do not freeze. Potency is destroyed by freezing; do not use if product has been frozen. Store in original packaging to protect from light (CDC Pink Book 2020). Storage information may vary by product; see manufacturer labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Afluria Quadrivalent, Afluria Tetra [Canadian product], Flucelvax Quadrivalent, FluLaval Tetra [Canadian product]: Discard multiple-dose vials 28 days after initial entry (excluding Flucelvax Quadrivalent [US product]). Between uses, the multiple-dose vial should be stored at 2°C to 8°C (36°F to 46°F). The maximum recommended number of needle punctures varies per product; see product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Fluad (Canadian labeling), Fluad Pediatric [Canadian product]: May be used if exposed to temperatures between 8°C to 25°C for &lt;2 hours.</p></div>
<div class="block meg drugH1Div" id="F25734123"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">In the US, the appropriate Centers for Disease Control and Prevention (CDC)-approved Vaccine Information Statement (VIS) must be provided to the patient/caregiver before administering each dose of this vaccine; the VIS edition date and date it was provided to the patient/caregiver should be recorded as required by US law; VIS is available at <a href="/external-redirect?target_url=http%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fhcp%2Fvis%2Fvis-statements%2Fflu.html&amp;token=i%2FT%2Fo2k6OLX6THAlHOY5IA5jGKSiJvxwNnmNCErfziwUYKRutfar2OJecb3NZBuk69UGq4WB70REX6D0Wkg7rA%3D%3D&amp;TOPIC_ID=12940" target="_blank">http://www.cdc.gov/vaccines/hcp/vis/vis-statements/flu.html</a>.</p></div>
<div class="block usep drugH1Div" id="F53569931"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Active immunization against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine.</p>
<table border="1" frame="border" rules="all">
<colgroup><col align="center"/>
<col align="center"/>
<col align="left"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">Trade Name</p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">Manufacturer</p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">Vaccine Type<sup>a</sup></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">Approval Age</p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="center" colspan="4">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup> IIV4 = quadrivalent inactivated influenza vaccine; ccIIV4 = quadrivalent cell culture-based inactivated influenza vaccine; aIIV4 = quadrivalent adjuvanted, inactivated influenza vaccine; HD-IIV4 = high-dose quadrivalent inactivated influenza vaccine; aIIV3 = trivalent adjuvanted inactivated influenza vaccine.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center" colspan="4">
<p style="text-indent:0em;text-align:left;">
<b>
<i>US Labeling</i></b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Afluria Quadrivalent</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Seqirus</p></td>
<td align="left">
<p style="text-indent:0em;">IIV4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≥6 months</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Fluarix Quadrivalent</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">GlaxoSmithKline</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">IIV4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≥6 months</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Flucelvax Quadrivalent</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Seqirus</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">ccIIV4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≥6 months</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">FluLaval Quadrivalent</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">ID Biomedical Corporation of Quebec</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">IIV4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≥6 months</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Fluzone Quadrivalent</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Sanofi Pasteur</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">IIV4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≥6 months</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Fluad Quadrivalent</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Seqirus</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">aIIV4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≥65 years</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Fluzone High-Dose Quadrivalent</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Sanofi Pasteur</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">HD-IIV4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≥65 years</p></td></tr>
<tr>
<td align="center" colspan="4">
<p style="text-indent:0em;text-align:left;">
<b>
<i>Canadian Labeling</i></b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Fluad Pediatric</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Seqirus Canada</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">aIIV3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">6 months to &lt;2 years</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Flucelvax Quad</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Seqirus Canada</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">ccIIV4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≥6 months</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">FluLaval Tetra</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">ID Biomedical Corporation of Quebec</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">IIV4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≥6 months</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Fluzone Quadrivalent</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Sanofi Pasteur</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">IIV4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≥6 months</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Influvac Tetra</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">BGP Pharma</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">IIV4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≥6 months</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Afluria Tetra</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Seqirus Canada</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">IIV4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≥5 years</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Fluad</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Seqirus Canada</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">aIIV3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≥65 years</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Fluzone High-Dose Quadrivalent</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Sanofi Pasteur</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">HD-IIV4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≥65 years</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Recommendations for annual <span style="text-decoration: underline">seasonal</span> influenza vaccination:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>The Advisory Committee on Immunization Practices (ACIP</i>) recommends routine annual vaccination with the seasonal influenza vaccine for all persons ≥6 months of age who do not have contraindications to the vaccine. For pediatric patients, the ACIP and AAP do not have a preferential recommendation for an influenza vaccine product; all products available for the 2023–2024 influenza season are quadrivalent (AAP 2023; CDC/ACIP [Grohskopf 2023]).</p>
<p style="text-indent:-2em;margin-left:6em;">• Persons 6 to 23 months of age: Any age- and risk factor-appropriate product may be used.</p>
<p style="text-indent:-2em;margin-left:6em;">• Persons 2 to 18 years of age: Any age- and risk factor-appropriate product may be used, including the live attenuated vaccine (LAIV4).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>The Canadian National Advisory Committee on Immunization (NACI)</i> recommends annual vaccination with seasonal influenza vaccine for all persons ≥6 months of age who do not have contraindications to the vaccine (NACI 2023). The following influenza vaccine preferences should be considered:</p>
<p style="text-indent:-2em;margin-left:6em;">• Persons 6 to 23 months of age: A quadrivalent influenza vaccine authorized for this age group is preferred; trivalent inactivated influenza vaccine (aIIV3; Fluad Pediatric) may be used if a quadrivalent vaccine is not available. Despite Health Canada approval down to 6 months of age, NACI does not recommend Influvac Tetra in this age group (due to insufficient efficacy evidence).</p>
<p style="text-indent:-2em;margin-left:6em;">• Persons 2 to 18 years of age: Any age- and risk factor-appropriate quadrivalent product may be used, including LAIV4; trivalent products for this age group are not available. Despite Health Canada approval down to 6 months of age, NACI recommends use of Influvac Tetra only in ages ≥3 years due to insufficient efficacy evidence in &lt;3 years of age.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Prioritization when vaccine supply is limited:</b></p>
<p style="text-indent:-2em;margin-left:4em;">When vaccine supply is limited, target groups for vaccination (those at higher risk of complications from influenza infection and their close contacts) include the following; see guidelines for details (CDC/ACIP [Grohskopf 2023]; NACI 2023):</p>
<p style="text-indent:-2em;margin-left:6em;">• All infants ≥6 months and children 12 to 59 months of age</p>
<p style="text-indent:-2em;margin-left:6em;">• Persons ≥50 years of age (≥65 years in Canada)</p>
<p style="text-indent:-2em;margin-left:6em;">• Residents of nursing homes and other long-term care facilities</p>
<p style="text-indent:-2em;margin-left:6em;">• Persons with chronic pulmonary disorders (including asthma), cardiovascular system disorders (except isolated hypertension), or renal, hepatic, neurologic, hematologic, or metabolic disorders (including diabetes mellitus). <b>Note:</b> The Canadian NACI excludes persons with isolated migraine or psychiatric conditions.</p>
<p style="text-indent:-2em;margin-left:6em;">• Persons who have immunosuppression due to any cause (including immunosuppression caused by medications or HIV)</p>
<p style="text-indent:-2em;margin-left:6em;">• Infants, children, and adolescents (6 months to 18 years) who are receiving long-term aspirin therapy or salicylate-containing medications and therefore, may be at risk for developing Reye syndrome after influenza infection</p>
<p style="text-indent:-2em;margin-left:6em;">• Persons who are or will be pregnant during influenza season</p>
<p style="text-indent:-2em;margin-left:6em;">• Indigenous peoples (including American Indian and Alaska Native persons)</p>
<p style="text-indent:-2em;margin-left:6em;">• Persons with extreme obesity (BMI ≥40 in adults)</p>
<p style="text-indent:-2em;margin-left:6em;">• Household contacts (≥6 months of age) and caregivers of neonates, infants, and children aged &lt;5 years (particularly neonates and infants &lt;6 months) and adults ≥50 years</p>
<p style="text-indent:-2em;margin-left:6em;">• Household contacts (≥6 months of age) and caregivers of persons with medical conditions which put them at higher risk of complications from influenza infection</p>
<p style="text-indent:-2em;margin-left:6em;">• Health care personnel, including students in these professions, and other persons not directly involved in patient care who may be exposed to infectious agents (eg, clerical, housekeeping, volunteers)</p>
<p style="text-indent:-2em;margin-left:6em;">• Persons who provide services within closed or relatively closed settings to persons at high risk (Canadian recommendation only)</p>
<p style="text-indent:-2em;margin-left:6em;">• Persons who provide essential community services (Canadian recommendation only)</p>
<p style="text-indent:-2em;margin-left:6em;">• Persons in direct contact with poultry infected with avian influenza during culling operations (Canadian recommendation only)</p></div>
<div class="block mst drugH1Div" id="F9560326"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">COVID-19 vaccine may be confused with influenza virus vaccine. Medication errors have occurred when COVID-19 vaccine was inadvertently administered instead of influenza virus vaccine (and vice versa). These products may be stored in close proximity to each other. Confirm the correct vaccine has been selected prior to administration (ISMP/NAN 2021).</p>
<p style="text-indent:-2em;margin-left:4em;">Fluarix may be confused with Flarex.</p>
<p style="text-indent:2em;">Fluzone Quadrivalent may be confused with Fluzone High-Dose Quadrivalent [CAN]</p>
<p style="text-indent:-2em;margin-left:4em;">Influenza virus vaccine may be confused with flumazenil, perflutren lipid microspheres.</p>
<p style="text-indent:-2em;margin-left:4em;">Influenza virus vaccine may be confused with tetanus toxoid and tuberculin products. IIV may be confused with PPD. Medication errors have occurred when tuberculin skin tests (PPD) have been inadvertently administered instead of tetanus toxoid products and influenza virus vaccine. These products are refrigerated and often stored in close proximity to each other.</p>
<p style="text-indent:-2em;margin-left:4em;">Influenza virus vaccine may be confused with insulin. Medication errors have occurred when insulin was inadvertently administered instead of influenza virus vaccine. These products are refrigerated and may be stored in close proximity to each other.</p>
<p style="text-indent:-2em;margin-left:4em;">Influenza virus vaccine may be confused with COVID-19 vaccines. Medication errors have occurred when COVID-19 vaccine was inadvertently administered instead of influenza virus vaccine.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Fluarix [US and multiple international markets] may be confused with Flarex brand name for fluorometholone [US and multiple international markets] and Fluorex brand name for fluoride [France]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299519"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6221011"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetaminophen: May diminish the therapeutic effect of Vaccines. Management: Consider avoiding routine prophylactic use of acetaminophen before or during vaccine administration when possible. Acetaminophen is still recommended to treat fevers and/or pain that occurs after vaccination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anti-CD20 B-Cell Depleting Therapies: May diminish the therapeutic effect of Influenza Virus Vaccines. Management: Administer influenza vaccines 2 weeks prior to starting anti-CD20 B-cell depleting therapies. Vaccination of patients treated with these agents in the past 6 months is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May diminish the therapeutic effect of Influenza Virus Vaccines. Management: Administer influenza vaccines at least 2 weeks prior to initiation of systemic corticosteroids at immunosuppressive doses. Influenza vaccines administered less than 14 days prior to or during such therapy should be repeated 3 months after therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxofylline: Influenza Virus Vaccine (Inactivated) may increase the serum concentration of Doxofylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elivaldogene Autotemcel: May enhance the adverse/toxic effect of Vaccines. Specifically, there may be a greater risk for contracting an infection from any live vaccine. Elivaldogene Autotemcel may diminish the therapeutic effect of Vaccines. Management: Administration of vaccines is not recommended in the 6 weeks before myeloablative conditioning, and until hematologic recovery after elivaldogene autotemcel treatment.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting fingolimod. If vaccinated during fingolimod therapy, revaccinate 2 to 3 months after fingolimod discontinuation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Cytotoxic Chemotherapy): May diminish the therapeutic effect of Influenza Virus Vaccines. Management: Administer influenza vaccines at least 2 weeks prior to initiating chemotherapy if possible. If vaccination occurs less than 2 weeks prior to or during chemotherapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Miscellaneous Oncologic Agents): May diminish the therapeutic effect of Influenza Virus Vaccines. Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Therapeutic Immunosuppressant Agents): May diminish the therapeutic effect of Influenza Virus Vaccines. Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate 2 to 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: May diminish the therapeutic effect of Influenza Virus Vaccines. Management: Administer influenza vaccines at least 2 weeks prior to initiating methotrexate if possible. If vaccination occurs less than 2 weeks prior to or during methotrexate therapy, revaccinate 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Conjugate Vaccine (13-Valent): May diminish the therapeutic effect of Influenza Virus Vaccine (Inactivated). Influenza Virus Vaccine (Inactivated) may diminish the therapeutic effect of Pneumococcal Conjugate Vaccine (13-Valent).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propacetamol: May diminish the therapeutic effect of Vaccines. Management: Consider avoiding routine prophylactic use of propacetamol before or during vaccine administration when possible. Propacetamol is still recommended to treat fevers and/or pain that occurs after vaccination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Siponimod: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Avoid administration of vaccines (inactivated) during treatment with siponimod and for 1 month after discontinuation due to potential decreased vaccine efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teplizumab: May diminish the therapeutic effect of Influenza Virus Vaccines. Management: Influenza virus vaccines are not recommended in the 2 weeks prior to teplizumab treatment, during treatment, or for 6 weeks after treatment. Reduced efficacy of the vaccine may occur if administer to patients taking teplizumab.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teplizumab: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Vaccination with inactivated or non-replicating vaccines is not recommended in the 2 weeks prior to teplizumab therapy, during treatment, or for 6 weeks following completion of therapy.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block rep_considerations drugH1Div" id="F54127878"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Using data prospectively collected from the Pregnancy Study Online (PRESTO), an internet-based preconception cohort study of patients planning to become pregnant, use of the seasonal influenza vaccine by either partner did not adversely affect the probability of conceiving (time and date of influenza vaccination in proximity to pregnancy was self-reported) (Orta 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Influenza vaccination with any licensed, recommended, age-appropriate vaccine is recommended for all patients who may become pregnant during the influenza season and who do not otherwise have contraindications to the vaccine (CDC/ACIP [Grohskopf 2023]).</p></div>
<div class="block pri drugH1Div" id="F9600926"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Inactivated influenza vaccine (IIV) has not been shown to cause fetal harm when given to pregnant patients, although information related to use in the first trimester is relatively limited (CDC/ACIP [Grohskopf 2023]).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">• Outcome data following exposure to the seasonal Fluarix and FluLaval trivalent and quadrivalent IIV are available from the GlaxoSmithKline pregnancy registry. Between 2014 and 2019, there were 507 reported US exposures with prospectively collected data (115 with outcome information); among these there were 84 first-trimester exposures (54 lost to follow-up). Also during this time period, there were 676 reports from global sources (493 with prospectively collected data; 186 with outcome information). Among the US pregnancies with known outcomes, 87.8% resulted in a live birth with no congenital anomalies. There were no live-born infants with first-trimester exposure to the seasonal IIV diagnosed with a congenital anomaly. Among the global prospectively reported exposures with known outcomes (n=186), 61.3% resulted in live birth with no congenital anomalies and 35.5% were ongoing. The registry also collected data for spontaneous abortion, fetal death/stillbirth; based on available data, no safety signals were identified (Nwoji 2022).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">• Outcome data following exposure to the seasonal quadrivalent IIV is also available from the Sanofi Pasteur Fluzone Quadrivalent pregnancy registry. Between 2013 and 2019, there were 239 reported exposures from nine different countries (&gt;85% from the United States, Australia, and Canada). Of these, 210 exposures had prospectively collected data (62 with known pregnancy/obstetrical outcomes and 15 with known neonatal outcomes) and 29 exposures with retrospectively collected data (29 with known pregnancy/obstetrical outcomes and 28 with known neonatal outcomes). No congenital anomalies were reported in the prospectively collected cases. Congenital anomalies were reported in four cases reported retrospectively (talipes n=2, atrial septal defect n=1, CNS anomaly n=1). Based on available data, the rates of all neonatal and maternal outcomes observed were similar to rates reported in the general population and no safety signals were identified (Ledlie 2022).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">• Outcome data following exposure to the Flucelvax quadrivalent vaccine are available from the US pregnancy registry. Using prospectively collected data from three influenza seasons between 2017 and 2020, there were 665 reported pregnancies and 659 live births. Maternal vaccination occurred during the first (27%), second (42%), and third (31%) trimesters. Based on available data, the rates of miscarriage and major birth defects observed were similar to rates reported in the general population.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">• Data from published studies, systematic reviews, and meta-analyses have not observed an increased risk of adverse pregnancy outcomes (including congenital anomalies, preterm birth, low birth weight, or fetal death) following maternal vaccination with IIV during pregnancy (Foo 2020; Jeong 2019; Macias Saint-Gerons 2021; Nunes 2016; Polyzos 2015; Xie 2023).</p>
<p style="text-indent:0em;margin-top:2em;">Maternal vaccination provides passive immunization to the newborn and decreases the risk of hospitalization due to influenza in infants &lt;6 months of age who are not eligible to be vaccinated (ACOG 2018).</p>
<p style="text-indent:0em;margin-top:2em;">The risk for severe illness and complications from influenza infection is increased during pregnancy, particularly during the second and third trimesters (CDC/ACIP [Grohskopf 2023]). Pregnant patients infected with influenza have a higher risk than nonpregnant patients of progression to pneumonia, hospitalization, and ICU admission (ACOG 2018). Influenza vaccination decreases the risk of laboratory-confirmed influenza and hospitalization in pregnant patients (Thompson 2014; Thompson 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Influenza vaccination is recommended annually and should be given to pregnant patients even if they were vaccinated in a prior pregnancy. The efficacy of influenza vaccination in pregnant patients is similar to nonpregnant adults (ACOG 2018). Influenza vaccination with any licensed, recommended, age-appropriate IIV or recombinant influenza vaccine (RIV) is recommended for all patients who are pregnant during the influenza season and who do not otherwise have contraindications to the vaccine (CDC/ACIP [Grohskopf 2023]). Vaccination may be done during any trimester (ACOG 2018). Vaccination of nonpregnant patients is typically offered by the end of October; however, to decrease the risk of infection to the neonate, consider vaccination of pregnant patients who are in their third trimester in July or August, or as soon as vaccine is available (CDC/ACIP [Grohskopf 2023]).</p>
<p style="text-indent:0em;margin-top:2em;">Pregnant patients should observe the same precautions as nonpregnant patients to reduce the risk of exposure to influenza and other respiratory infections (CDC/HHS 2023). When vaccine supply is limited, focus should be given to delivering the vaccine to patients who are pregnant or will be pregnant during the flu season, as well as contacts or caregivers of children &lt;5 years of age (particularly contacts of neonates and infants &lt;6 months of age) (CDC/ACIP [Grohskopf 2023]).</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to influenza vaccine is ongoing.</p>
<p style="text-indent:-2em;margin-left:2em;">• Persons exposed to Afluria Quadrivalent vaccine during pregnancy may contact the Seqirus registry at 855-358-8966 or via email at <a class="__cf_email__" data-cfemail="493c3a67242c2d202a282520272f263b24283d202627093a2c38203b3c3a672a2624" href="/cdn-cgi/l/email-protection">[email protected]</a>.</p>
<p style="text-indent:-2em;margin-left:2em;">• Health care providers may enroll patients exposed to Fluzone Quadrivalent during pregnancy in the Sanofi Pasteur vaccination registry at 1-800-822-2463.</p></div>
<div class="block mopp drugH1Div" id="F53569881"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Observe for syncope and hypersensitivity reaction for 15 minutes following administration (ACIP [Kroger 2023]). If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.</p></div>
<div class="block pha drugH1Div" id="F9600931"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Promotes immunity to seasonal influenza virus by inducing specific antibody production. Preparations from previous seasons must not be used.</p></div>
<div class="block phk drugH1Div" id="F9600933"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Most adults have antibody protection within 2 weeks of vaccination (CDC/ACIP [Grohskopf 2023]).</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Vaccine effectiveness declines at a variable rate, depending on virus subtypes, patient age, and other confounding factors (CDC/ACIP [Grohskopf 2023]).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F27657868"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Fluarix tetra | Vaxigrip tetra</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Afluria quad | Istivac4</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Efluelda | Fluarix tetra | Flucelvax tetra | Vaxigriptetra</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Afluria quad | Fluarix tetra | Fluquadri | Vaxigrip tetra</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Efluelda | Fluarix tetra | Vaxigrip tetra</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Vaxigrip tetra</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Fluarix tetra | Flucelvax tetra | Fluquadri | Vaxigrip tetra</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Efluelda | Fluarix tetra | Vaxigriptetra</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Fluquadri | Vaxigrip tetra</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Fluarix tetra | Fluquadri | Quadrivalent influenza vaccine | Vaxigrip tetra</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Efluelda | Fluarix tetra | Vaxigrip tetra</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Afluria tetra | Efluelda | Flucelvax tetra | Influsplit Tetra | Vaxigrip tetra</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Vaxigrip tetra</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Fluquadri | Vaxigriptetra</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Fluarix tetra | Vaxigriptetra</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Efluelda | Fluarix tetra | Flucelvax tetra | Vaxigrip tetra</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Efluelda | Fluarix tetra | Vaxigriptetra</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Efluelda | Fluarix tetra | Fluzone High Dose Quadrivalent | Influsplit Tetra | Vaxigrip tetra hs | Vaxigriptetra</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Fluarix tetra | Flucelvax tetra | Quadrivalent influenza vaccine</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Fluarix tetra | Flucelvax tetra | Vaxigrip tetra</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Fluarix tetra | Fluquadri | Vaxigrip tetra</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Vaxigriptetra</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Flucelvax tetra | Vaxigrip tetra</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Fluquadri | Vaxigrip tetra</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Quadrivalent influenza vaccine</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Fluquadri | Vaxiflu 4</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Efluelda | Fluarix tetra | Flucelvax tetra | Vaxigrip tetra</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Br flutec iii tetra | Br flutech I tetra | Fluarix tetra | Gcflu quadrivalent | Gcflu quadrivalent multi | Kovax flu tetra | Kovax influ tetra | Teratect | Vaxiflu tetra | Vaxigrip tetra</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Quadrivalent influenza vaccine | Vaxigrip tetra</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Fluarix tetra | Vaxigrip tetra | Vaxigriptetra</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Flucelvax tetra | Vaxigrip tetra</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Fluarix tetra | Vaxigriptetra</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Fluzactal Tetra | Fluzone quadrivalent | Vaxigrip tetra</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Fluarix tetra | Fluquadri | Vaxigrip tetra</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Efluelda | Flucelvax tetra</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Fluarix tetra | Vaxigriptetra</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Afluria quad | Afluria quad junior | Fluarix tetra | Fluquadri</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Fluarix tetra | Fluquadri | Vaxigriptetra</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Fluarix tetra | Fluquadri</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Vaxigrip tetra</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Fluarix tetra | Vaxiflu 4 | Vaxigriptetra</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Afluria quadrivalent | Fluarix quadrivalent | Fluzone High Dose Quadrivalent</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Efluelda | Vaxigrip tetra</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Fluquadri | Vaxigrip tetra</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Fluarix Quadrivalent 2020/2021 | Influvac 2015/2016 | Influvac Tetra 2021 | Vaxigrip</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Vaxigriptetra</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Flu M Tetra | Ultrix quadri</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Efluelda | Fluarix tetra | Vaxigriptetra</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Fluarix tetra | Fluquadri | Vaxigrip tetra</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Vaxigrip tetra</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Vaxigrip tetra</span>;</li>
<li>
<span class="countryCode">(SV)</span> <span class="country">El Salvador</span><span class="countrySeparator">: </span><span class="drugName">Vaxigriptetra</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Fluarix tetra | Fluquadri | Gcflu quadrivalent | Vaxigrip tetra</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Vaxigrip tetra | Vaxigriptetra</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Fluarix tetra | Vaxigrip tetra</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Fluarix tetra | Vaxigrip tetra</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Vaxigrip tetra</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Fluquadri | Vaxigriptetra</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Fluquadri</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Fluarix tetra | Vaxigrip tetra</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Afluria.1">
<a name="Afluria.1"></a>Afluria Quadrivalent (influenza vaccine) [prescribing information]. Summit, NJ: Seqirus USA Inc; received June 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Seqirus.3">
<a name="Seqirus.3"></a>Afluria Tetra (quadrivalent inactivated influenza vaccine [split virion]) [product monograph]. Kirkland, Quebec, Canada: Seqirus Canada Inc; April 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Seqirus.2">
<a name="Seqirus.2"></a>Afluria Tetra (quadrivalent inactivated influenza vaccine [split virion]) [product monograph]. Kirkland, Quebec, Canada: Seqirus Canada Inc; May 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/influenza-virus-vaccines-inactivated-iiv4-pediatric-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37641879">
<a name="37641879"></a>American Academy of Pediatrics (AAP) Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children, 2023-2024. <i>Pediatrics</i>. 2023a;152(4):e2023063772. doi:10.1542/peds.2023-063772<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/influenza-virus-vaccines-inactivated-iiv4-pediatric-drug-information/abstract-text/37641879/pubmed" id="37641879" target="_blank">37641879</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37641884">
<a name="37641884"></a>American Academy of Pediatrics (AAP) Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children, 2023-2024. <i>Pediatrics</i>. Published online August 29, 2023b. doi:10.1542/peds.2023-063773<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/influenza-virus-vaccines-inactivated-iiv4-pediatric-drug-information/abstract-text/37641884/pubmed" id="37641884" target="_blank">37641884</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29578985">
<a name="29578985"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG Committee Opinion No. 732: influenza vaccination during pregnancy. <i>Obstet Gynecol</i>. 2018;131(4):e109-e114.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/influenza-virus-vaccines-inactivated-iiv4-pediatric-drug-information/abstract-text/29578985/pubmed" id="29578985" target="_blank">29578985</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23810001">
<a name="23810001"></a>Auffret M, Béné J, Gautier S, et al. Pharmacovigilance monitoring of a cohort of pregnant women vaccinated against influenza A(H1N1) variant virus in the Nord-Pas de Calais region of northern France. <i>Eur J Obstet Gynecol Reprod Biol</i>. 2013;170(1):114-118.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/influenza-virus-vaccines-inactivated-iiv4-pediatric-drug-information/abstract-text/23810001/pubmed" id="23810001" target="_blank">23810001</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23580737">
<a name="23580737"></a>Baxter R, Bakshi N, Fireman B, et al. Lack of association of Guillain-Barre syndrome with vaccinations. <i>Clin Infect Dis</i>. 2013;57(2):197-204.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/influenza-virus-vaccines-inactivated-iiv4-pediatric-drug-information/abstract-text/23580737/pubmed" id="23580737" target="_blank">23580737</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29961606">
<a name="29961606"></a>Brady RC, Jackson LA, Frey SE, et al. Randomized trial comparing the safety and antibody responses to live attenuated versus inactivated influenza vaccine when administered to breastfeeding women. <i>Vaccine</i>. 2018;36(31):4663-4671. doi:10.1016/j.vaccine.2018.06.036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/influenza-virus-vaccines-inactivated-iiv4-pediatric-drug-information/abstract-text/29961606/pubmed" id="29961606" target="_blank">29961606</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/influenza-virus-vaccines-inactivated-iiv4-pediatric-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Centers for Disease Control and Prevention (CDC). Immunogenicity, efficacy, and effectiveness of influenza vaccines. <a href="https://www.cdc.gov/flu/professionals/acip/2018-2019/background/immunogenicity.htm" target="_blank">https://www.cdc.gov/flu/professionals/acip/2018-2019/background/immunogenicity.htm</a>. Updated August 23, 2018. Accessed August 26, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2">
<a name="CDC.2"></a>Centers for Disease Control and Prevention (CDC), "Note to Providers: Febrile Seizures Associated With TIV &amp; PCV13." Available at <a href="https://www.cdc.gov/vaccines/pubs/vis/tiv-pcv-note.htm" target="_blank">http://www.cdc.gov/vaccines/pubs/vis/tiv-pcv-note.htm</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.4">
<a name="CDC.4"></a>Centers for Disease Control and Prevention (CDC); US Department of Health and Human Services (HHS). Flu &amp; pregnancy. <a href="https://www.cdc.gov/flu/highrisk/pregnant.htm" target="_blank">https://www.cdc.gov/flu/highrisk/pregnant.htm</a>. Updated September 7, 2023. Accessed September 11, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.6">
<a name="CDC.6"></a>Centers for Disease Control and Prevention (CDC). Vaccine storage and handling. In: Hamborsky J, Kroger A, Wolfe C, eds. <i>Epidemiology and Prevention of Vaccine-Preventable Diseases (CDC Pink Book)</i>. 13th ed. Public Health Foundation; 2015. <a href="https://www.cdc.gov/vaccines/pubs/pinkbook/vac-storage.html" target="_blank">https://www.cdc.gov/vaccines/pubs/pinkbook/vac-storage.html</a> Updated July 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27166466">
<a name="27166466"></a>Cross GB, Moghaddas J, Buttery J, Ayoub S, Korman TM. Don't aim too high: avoiding shoulder injury related to vaccine administration. <i>Aust Fam Physician</i>. 2016;45(5):303-306.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/influenza-virus-vaccines-inactivated-iiv4-pediatric-drug-information/abstract-text/27166466/pubmed" id="27166466" target="_blank">27166466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25119609">
<a name="25119609"></a>DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults.<i> N Engl J Med.</i> 2014;371(7):635-645. doi: 10.1056/NEJMoa1315727.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/influenza-virus-vaccines-inactivated-iiv4-pediatric-drug-information/abstract-text/25119609/pubmed" id="25119609" target="_blank">25119609</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29388196">
<a name="29388196"></a>Demicheli V, Jefferson T, Ferroni E, et al. Vaccines for preventing influenza in healthy adults. <i>Cochrane Database Syst Rev</i>. 2018;2:CD001269. doi: 10.1002/14651858.CD001269.pub6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/influenza-virus-vaccines-inactivated-iiv4-pediatric-drug-information/abstract-text/29388196/pubmed" id="29388196" target="_blank">29388196</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23319691">
<a name="23319691"></a>Flowers CR, Seidenfeld J, Bow EJ, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2013;31(6):794-810.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/influenza-virus-vaccines-inactivated-iiv4-pediatric-drug-information/abstract-text/23319691/pubmed" id="23319691" target="_blank">23319691</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Seqirus.4">
<a name="Seqirus.4"></a>Fluad Pediatric and Fluad (influenza vaccine) [product monograph]. Kirkland, Quebec, Canada: Seqirus Canada Inc; September 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fluad.3">
<a name="Fluad.3"></a>Fluad Quadrivalent (influenza vaccine) [prescribing information]. Holly Springs, NC: Seqirus Inc; June 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GSK.1">
<a name="GSK.1"></a>Fluarix Quadrivalent (influenza vaccine) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; June 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Seqirus.6">
<a name="Seqirus.6"></a>Flucelvax Quad (influenza vaccine) [product monograph]. Kirkland, Quebec, Canada: Seqirus Canada Inc; May 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Seqirus.7">
<a name="Seqirus.7"></a>Flucelvax Quadrivalent (influenza vaccine) [prescribing information]. Holly Springs, NC: Seqirus Inc; June 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FluLaval.1">
<a name="FluLaval.1"></a>FluLaval Quadrivalent (influenza vaccine) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; June 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Biomed.1">
<a name="Biomed.1"></a>FluLaval Tetra (influenza vaccine) [product monograph]. Quebec, Quebec, Canada: ID Biomedical Corp of Quebec; April 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sanofi.1">
<a name="Sanofi.1"></a>Fluzone High-Dose Quadrivalent (influenza vaccine) [prescribing information]. Swiftwater, PA: Sanofi Pasteur Inc; June 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sanofi.2">
<a name="Sanofi.2"></a>Fluzone High-Dose Quadrivalent (influenza vaccine) [product monograph]. Toronto, Ontario, Canada: Sanofi Pasteur Ltd; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fluzone.4">
<a name="Fluzone.4"></a>Fluzone Quadrivalent 2023-2024 (influenza vaccine) [prescribing information]. Swiftwater, PA: Sanofi Pasteur Inc; July 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fluzone.3">
<a name="Fluzone.3"></a>Fluzone Quadrivalent 2023-2024 (influenza vaccine) [prescribing information]. Swiftwater, PA: Sanofi Pasteur Inc; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sanofi.3">
<a name="Sanofi.3"></a>Fluzone Quadrivalent (influenza vaccine) [product monograph]. Toronto, Ontario, Canada: Sanofi Pasteur Ltd; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32719088">
<a name="32719088"></a>Foo DYP, Sarna M, Pereira G, Moore HC, Fell DB, Regan AK. Early childhood health outcomes following in utero exposure to influenza vaccines: a systematic review. <i>Pediatrics</i>. 2020;146(2):e20200375. doi:10.1542/peds.2020-0375<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/influenza-virus-vaccines-inactivated-iiv4-pediatric-drug-information/abstract-text/32719088/pubmed" id="32719088" target="_blank">32719088</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23636163">
<a name="23636163"></a>Foster SL, Davis MV. Vaccine administration: preventing serious shoulder injuries. <i>J Am Pharm Assoc</i> (2003). 2013;53(1):102-103. doi:10.1331/JAPhA.2013.13503<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/influenza-virus-vaccines-inactivated-iiv4-pediatric-drug-information/abstract-text/23636163/pubmed" id="23636163" target="_blank">23636163</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23840621">
<a name="23840621"></a>Greene SK, Rett MD, Vellozzi C, et al. Guillain-Barré Syndrome, Influenza Vaccination, and Antecedent Respiratory and Gastrointestinal Infections: A Case-Centered Analysis in the Vaccine Safety Datalink, 2009-2011. <i>PLoS One</i>. 2013;8(6):e67185.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/influenza-virus-vaccines-inactivated-iiv4-pediatric-drug-information/abstract-text/23840621/pubmed" id="23840621" target="_blank">23840621</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29273128">
<a name="29273128"></a>Greenhawt M, Turner PJ, Kelso JM. Administration of influenza vaccines to egg allergic recipients: A practice parameter update 2017. <i>Ann Allergy Asthma Immunol</i>. 2018;120(1):49-52. doi: 10.1016/j.anai.2017.10.020.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/influenza-virus-vaccines-inactivated-iiv4-pediatric-drug-information/abstract-text/29273128/pubmed" id="29273128" target="_blank">29273128</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Grohskopf.1">
<a name="Grohskopf.1"></a>Grohskopf LA, Blanton LH, Ferdinands JM, Chung JR, Broder KR, Talbot HK. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices — United States, 2023–24 influenza season. <i>MMWR Recomm Rep</i>. 2023;72(2):1-25. doi:10.15585/mmwr.rr7202a1</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Grohskopf.2">
<a name="Grohskopf.2"></a>Grohskopf LA, Blanton LH, Ferdinands JM, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices - United States, 2022-23 influenza season. <i>MMWR Recomm Rep</i>. 2022;71(1):1-28. doi: 10.15585/mmwr.rr7101a1</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-BGP.1">
<a name="BGP.1"></a>Influvac Tetra (influenza vaccine) [product monograph]. Etobicoke, Ontario, Canada: BGP Pharma ULC; November 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ISMP.1">
<a name="ISMP.1"></a>Institute for Safe Medication Practices (ISMP); The National Alert Network (NAN). Mix-ups between the influenza (flu) vaccine and COVID-19 vaccine. https://www.ismp.org/alerts/mix-ups-between-influenza-flu-vaccine-and-covid-19-vaccines. Published October 15, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/influenza-virus-vaccines-inactivated-iiv4-pediatric-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31412058">
<a name="31412058"></a>Jeong S, Jang EJ, Jo J, Jang S. Effects of maternal influenza vaccination on adverse birth outcomes: a systematic review and Bayesian meta-analysis. <i>PLoS One</i>. 2019;14(8):e0220910. doi:10.1371/journal.pone.0220910<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/influenza-virus-vaccines-inactivated-iiv4-pediatric-drug-information/abstract-text/31412058/pubmed" id="31412058" target="_blank">31412058</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kroger.1">
<a name="Kroger.1"></a>Kroger A, Bahta L, Long S, Sanchez P. General best practice guidelines for immunization: best practices guidance of the Advisory Committee on Immunization Practices (ACIP). <a href="https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html" target="_blank">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html</a>. Accessed September 13, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23810252">
<a name="23810252"></a>Kwong JC, Vasa PP, Campetelli MA, et al. Risk of Guillain-Barré syndrome after seasonal influenza vaccination and influenza health-care encounters: a self-controlled study. <i>Lancet Infect Dis</i>. 2013;13(9):769-776.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/influenza-virus-vaccines-inactivated-iiv4-pediatric-drug-information/abstract-text/23810252/pubmed" id="23810252" target="_blank">23810252</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34520127">
<a name="34520127"></a>Ledlie S, Gandhi-Banga S, Shrestha A, Mallett Moore T, Khromava A. Exposure to quadrivalent influenza vaccine during pregnancy: results from a global pregnancy registry. <i>Influenza Other Respir Viruses</i>. 2022;16(1):90-100. doi:10.1111/irv.12897<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/influenza-virus-vaccines-inactivated-iiv4-pediatric-drug-information/abstract-text/34520127/pubmed" id="34520127" target="_blank">34520127</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/influenza-virus-vaccines-inactivated-iiv4-pediatric-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32972737">
<a name="32972737"></a>Macias Saint-Gerons D, Solà Arnau I, De Mucio B, et al. Adverse events associated with the use of recommended vaccines during pregnancy: an overview of systematic reviews. <i>Vaccine</i>. 2021;39(suppl 2):B12-B26. doi:10.1016/j.vaccine.2020.07.048<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/influenza-virus-vaccines-inactivated-iiv4-pediatric-drug-information/abstract-text/32972737/pubmed" id="32972737" target="_blank">32972737</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NACI.2">
<a name="NACI.2"></a>National Advisory Committee on Immunization (NACI); Committee to Advise on Tropical Medicine and Travel (CATMAT). Canadian Immunization Guide. Public Health Agency of Canada website. <a href="http://www.phac-aspc.gc.ca/publicat/cig-gci/index-eng.php" target="_blank">http://www.phac-aspc.gc.ca/publicat/cig-gci/index-eng.php</a>. Published 2012. Updated March 2014. Accessed September 17, 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NACI.1">
<a name="NACI.1"></a>National Advisory Committee on Immunization (NACI). Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2022-2023. Public Health Agency of Canada website. <a href="https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/canadian-immunization-guide-statement-seasonal-influenza-vaccine-2022-2023.html" target="_blank">https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/canadian-immunization-guide-statement-seasonal-influenza-vaccine-2022-2023.html</a>. Updated June 8, 2022. Accessed September 26, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NACI.2">
<a name="NACI.2"></a>National Advisory Committee on Immunization (NACI). Statement on seasonal influenza vaccine for 2023-2024. Public Health Agency of Canada website. <a href="https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/national-advisory-committee-immunization-statement-seasonal-influenza-vaccine-2023-2024.html" target="_blank">https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/national-advisory-committee-immunization-statement-seasonal-influenza-vaccine-2023-2024.html</a>. Updated May 31, 2023. Accessed September 13, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIH.1">
<a name="NIH.1"></a>National Institutes of Health (NIH). Influenza and COVID-19. <a href="https://www.covid19treatmentguidelines.nih.gov/special-populations/influenza/" target="_blank">https://www.covid19treatmentguidelines.nih.gov/special-populations/influenza/</a>. Updated October 22, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27603545">
<a name="27603545"></a>Nunes MC, Aqil AR, Omer SB, Madhi SA. The effects of influenza vaccination during pregnancy on birth outcomes: a systematic review and meta-analysis. <i>Am J Perinatol</i>. 2016;33(11):1104-1114. doi:10.1055/s-0036-1586101<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/influenza-virus-vaccines-inactivated-iiv4-pediatric-drug-information/abstract-text/27603545/pubmed" id="27603545" target="_blank">27603545</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34082643">
<a name="34082643"></a>Nwoji U. Seasonal influenza vaccine exposure in pregnancy: 5-year results from a pregnancy registry. <i>Hum Vaccin Immunother.</i> 2022;18(1):1932213. doi:10.1080/21645515.2021.1932213<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/influenza-virus-vaccines-inactivated-iiv4-pediatric-drug-information/abstract-text/34082643/pubmed" id="34082643" target="_blank">34082643</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32409134">
<a name="32409134"></a>Orta OR, Hatch EE, Regan AK, et al. A prospective study of influenza vaccination and time to pregnancy. <i>Vaccine</i>. 2020;38(27):4246-4251. doi:10.1016/j.vaccine.2020.04.054<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/influenza-virus-vaccines-inactivated-iiv4-pediatric-drug-information/abstract-text/32409134/pubmed" id="32409134" target="_blank">32409134</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26444106">
<a name="26444106"></a>Polyzos KA, Konstantelias AA, Pitsa CE, Falagas ME. Maternal influenza vaccination and risk for congenital malformations: a systematic review and meta-analysis. <i>Obstet Gynecol</i>. 2015;126(5):1075-1084. doi:10.1097/AOG.0000000000001068<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/influenza-virus-vaccines-inactivated-iiv4-pediatric-drug-information/abstract-text/26444106/pubmed" id="26444106" target="_blank">26444106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19837254">
<a name="19837254"></a>Prymula R, Siegrist CA, Chlibek R, et al. Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials. <i>Lancet</i>. 2009;374(9698):1339-1350.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/influenza-virus-vaccines-inactivated-iiv4-pediatric-drug-information/abstract-text/19837254/pubmed" id="19837254" target="_blank">19837254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18258087">
<a name="18258087"></a>Rasmussen SA, Jamieson DJ, and Bresee JS, "Pandemic Influenza and Pregnant Women," <i>Emerg Infect Dis</i>, 2008, 14(1):95-100.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/influenza-virus-vaccines-inactivated-iiv4-pediatric-drug-information/abstract-text/18258087/pubmed" id="18258087" target="_blank">18258087</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24311479">
<a name="24311479"></a>Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. <i>Clin Infect Dis</i>. 2014;58(3):e44-e100.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/influenza-virus-vaccines-inactivated-iiv4-pediatric-drug-information/abstract-text/24311479/pubmed" id="24311479" target="_blank">24311479</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23967126">
<a name="23967126"></a>Schlaudecker EP, Steinhoff MC, Omer SB, et al. IgA and neutralizing antibodies to influenza a virus in human milk: a randomized trial of antenatal influenza immunization. <i>PLoS One</i>, 2013;8(8):e70867.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/influenza-virus-vaccines-inactivated-iiv4-pediatric-drug-information/abstract-text/23967126/pubmed" id="23967126" target="_blank">23967126</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/influenza-virus-vaccines-inactivated-iiv4-pediatric-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15665712">
<a name="15665712"></a>Skowronski DM, Bjornson G, Husain E, et al. Oculorespiratory syndrome after influenza immunization in children. <i>Pediatr Infect Dis J</i>. 2005;24(1):63-69.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/influenza-virus-vaccines-inactivated-iiv4-pediatric-drug-information/abstract-text/15665712/pubmed" id="15665712" target="_blank">15665712</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20427817">
<a name="20427817"></a>Steinhoff MC, Omer SB, Roy E, et al. Influenza immunization in pregnancy - antibody responses in mothers and infants. <i>N Engl J Med</i>. 2010;362(17):1644-1646.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/influenza-virus-vaccines-inactivated-iiv4-pediatric-drug-information/abstract-text/20427817/pubmed" id="20427817" target="_blank">20427817</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30307490">
<a name="30307490"></a>Thompson MG, Kwong JC, Regan AK, et al; PREVENT Workgroup. Influenza vaccine effectiveness in preventing influenza-associated hospitalizations during pregnancy: a multi-country retrospective test negative design study, 2010-2016.<i> Clin Infect Dis.</i> 2019;68(9):1444-1453. doi:10.1093/cid/ciy737<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/influenza-virus-vaccines-inactivated-iiv4-pediatric-drug-information/abstract-text/30307490/pubmed" id="30307490" target="_blank">30307490</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24280090">
<a name="24280090"></a>Thompson MG, Li DK, Shifflett P, et al; Pregnancy and Influenza Project Workgroup. Effectiveness of seasonal trivalent influenza vaccine for preventing influenza virus illness among pregnant women: a population-based case-control study during the 2010-2011 and 2011-2012 influenza seasons. <i>Clin Infect Dis</i>. 2014;58(4):449-457. doi: 10.1093/cid/cit750.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/influenza-virus-vaccines-inactivated-iiv4-pediatric-drug-information/abstract-text/24280090/pubmed" id="24280090" target="_blank">24280090</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tomblyn.1">
<a name="Tomblyn.1"></a>Tomblyn M, Chiller T, Einsele H, et al; Center for International Blood and Marrow Research; National Marrow Donor program; European Blood and Marrow Transplant Group; American Society of Blood and Marrow Transplantation; Canadian Blood and Marrow Transplant Group; Infectious Diseases Society of America; Society for Healthcare Epidemiology of America; Association of Medical Microbiology and Infectious Disease Canada; Centers for Disease Control and Prevention. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective [published correction in <i>Biol Blood Marrow Transplant</i>. 2010;16(2):294]. <i>Biol Blood Marrow Transplant</i>. 2009;15(10):1143-1238.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>US Food and Drug Administration, "FDA Updated Communication on Use of Jet Injectors With Inactivated Influenza Vaccines." Last updated October 2011. Available at <a href="http://www.fda.gov/BiologicsBloodVaccines/Vaccines/QuestionsaboutVaccines/ucm276773.htm" target="_blank">http://www.fda.gov/BiologicsBloodVaccines/Vaccines/QuestionsaboutVaccines/ucm276773.htm</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Guiding principles for immunization activities during the COVID-19 pandemic: interim guidance, 26 March 2020. Published March 26, 2020. Available at https://apps.who.int/iris/handle/10665/331590
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36870879">
<a name="36870879"></a>Xie S, Monteiro K, Gjelsvik A. The association between maternal influenza vaccination during pregnancy and adverse birth outcomes in the United States: Pregnancy Risk Assessment Monitoring System (PRAMS). <i>Vaccine</i>. 2023;41(13):2300-2306. doi:10.1016/j.vaccine.2023.02.074<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/influenza-virus-vaccines-inactivated-iiv4-pediatric-drug-information/abstract-text/36870879/pubmed" id="36870879" target="_blank">36870879</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18799552">
<a name="18799552"></a>Zaman K, Roy E, Arifeen SE, Rahman M, et al, "Effectiveness of Maternal Influenza Immunization in Mothers and Infants," <i>N Engl J Med</i>, 2008, 359(15):1555-64.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/influenza-virus-vaccines-inactivated-iiv4-pediatric-drug-information/abstract-text/18799552/pubmed" id="18799552" target="_blank">18799552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21119083">
<a name="21119083"></a>Zuccotti G, Pogliani L, Pariani E, et al. Transplacental antibody transfer following maternal immunization with a pandemic 2009 influenza A(H1N1) MF59-adjuvanted vaccine. <i>JAMA</i>. 2010;304(21):2360-2361.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/influenza-virus-vaccines-inactivated-iiv4-pediatric-drug-information/abstract-text/21119083/pubmed" id="21119083" target="_blank">21119083</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12940 Version 361.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
